Search results
Results from the WOW.Com Content Network
Gigantism (Greek: γίγας, gígas, "giant", plural γίγαντες, gígantes), also known as giantism, is a condition characterized by excessive growth and height significantly above average. In humans, this condition is caused by over-production of growth hormone in childhood.
The long-acting forms of these drugs must be injected every 2 to 4 weeks for effective treatment. Most people with acromegaly respond to this medication. In many people with acromegaly, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment.
GH treatment usually decreases insulin sensitivity, [24] but some studies showed no evidence for increased diabetes incidence in GH-treated adult hypopituitary patients. [ 25 ] In past it was believed that GH treatment could increase the cancer risk; a large study recently concluded that "With relatively short follow-up, the overall primary ...
Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; [3] [medical citation needed] it typically results from a pituitary adenoma.In children with hyperpituitarism, disruption of growth regulation is rare, either because of hormone hypersecretion or because of manifestations caused by local compression of the adenoma.
Local gigantism affecting second toe of a child Local gigantism or localised gigantism is a condition in which a certain part of the body acquires larger than normal size due to excessive growth of the anatomical structures or abnormal accumulation of substances.
If there is an excess of growth hormone, it is usually because of over-secretion of somatotrope cells in the anterior pituitary gland. A significant amount of excess somatotrope secretion before puberty or before the end of new bone tissue growth can lead to gigantism, a disease that causes excess growth of body (e.g. being over 7 ft. tall) and unusually long limbs.
Treatment Depends on type Autoimmune polyendocrine syndromes ( APSs ), also called polyglandular autoimmune syndromes ( PGASs ) [ 3 ] or polyendocrine autoimmune syndromes ( PASs ), are a heterogeneous group [ 4 ] of rare diseases characterized by autoimmune activity against more than one endocrine organ , although non-endocrine organs can be ...
People with LS are unresponsive to growth hormone therapy; the disease is instead treated mainly with recombinant IGF-1, Mecasermin. [ 3 ] Evidence has suggested that people with Laron syndrome have a reduced risk of developing cancer and diabetes mellitus type II , with a significantly reduced incidence and delayed age of onset of these ...